SYNEURX INTERNATIONAL (TAIWAN) CORP. SyneuRx International (Taiwan) Corp. Share Price
Equities
6575
TW0006575004
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.2 TWD | -.--% |
|
-.--% | -.--% |
| Sales 2022 | - | Sales 2023 | 1.32 42.67 105.38 | Capitalization | 2.33B 75.09B 185B |
|---|---|---|---|---|---|
| Net income 2022 | -353M -11.39B -28.14B | Net income 2023 | -133M -4.29B -10.6B | EV / Sales 2022 | - |
| Net cash position 2022 | 48.6M 1.57B 3.87B | Net cash position 2023 | 87.71M 2.83B 6.99B | EV / Sales 2023 | 1,693,594,981 x |
| P/E ratio 2022 |
-5.89
x | P/E ratio 2023 |
-17.2
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 80.14% |
More Fundamentals
* Assessed data
More news
3 years
8.36
90.00
5 years
8.3690.00
10 years
8.36264.99
| Managers | Title | Age | Since |
|---|---|---|---|
Kuo Chuan Tsai
CEO | Chief Executive Officer | - | 01/04/13 |
I Chen Yan
DFI | Director of Finance/CFO | - | 10/04/16 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mao Chung Chang
BRD | Director/Board Member | - | 30/06/20 |
Kuo Chuan Tsai
CEO | Chief Executive Officer | - | 01/04/13 |
Cheng Wen Wu
BRD | Director/Board Member | - | 25/06/17 |
SyneuRx International Taiwan Corp is a Taiwan-based company mainly engaged in the development of new drugs. The Company is mainly engaged in the research and development of new drugs for treatment of coronavirus disease (COVID-19), schizophrenia, dementia and depression. Its clinical trials include SNB01 COVID-19 Antiviral, SND13 Adult Schizophrenia Study, SND12 Refractory Schizophrenia and SND11 Adolescent Schizophrenia.
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 72.06M | |
| +8.96% | 105B | |
| -1.43% | 104B | |
| +4.40% | 22.94B | |
| -12.15% | 22.34B | |
| -4.36% | 19.25B | |
| -39.98% | 17.08B | |
| -10.04% | 16.96B | |
| +6.79% | 14.16B | |
| +38.61% | 12.63B |
- Stock Market
- Equities
- 6575 Stock
